PEG-Containing Linkers for Conjugate Storage Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conjugates used in therapeutic, diagnostic, and labelling applications often face issues with storage stability and biological activity, particularly when cleavable linkers are used, leading to reduced shelf-life and effectiveness.
Innovation Solution
The use of PEG-containing linkers with a specific structure in conjugates, including a polyethylene glycol portion with a terminal end group of —CH2CH2OR, enhances storage stability and biological activity by stabilizing the conjugates and facilitating controlled release of payloads.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If cleavable linkers are used in conjugates, then payload release is facilitated, but storage stability and shelf-life are reduced
Solution Approach 1:
The linker is divided into distinct functional segments: a stable PEG backbone portion that maintains structural integrity during storage, and a cleavable payload-release portion that activates under specific conditions. This segmentation allows the linker to simultaneously provide storage stability through the robust PEG structure while enabling controlled payload release through the conditional cleavage mechanism.
Solution Approach 2:
The linker transitions from a static, stable configuration during storage to a dynamic, cleavable state upon activation. The PEG backbone maintains rigidity and stability during storage, while the cleavable portion remains dormant until triggered by specific physiological conditions or stimuli, at which point it dynamically cleaves to release the payload.
2Stability of the object's composition
If PEG-containing linkers with specific structure are used, then storage stability is improved, but conjugate structure complexity increases
Solution Approach 1:
The PEG linker utilizes controlled parameter variations including specific molecular weights, degrees of polymerization, and terminal end group configurations to optimize storage stability. By systematically adjusting these parameters within defined ranges, the invention achieves enhanced stability without requiring overly complex structural designs, balancing performance with structural simplicity.
Data Source
AI summary
The invention relates to a conjugate of a protein or peptide with a therapeutic, diagnostic or labelling agent, said conjugate containing a protein or peptide bonding portion and a polyethylene glycol portion; in which said protein or peptide bonding portion has the general formula:in which Pr represents said protein or peptide, each Nu represents a nucleophile present in or attached to the protein or peptide, each of A and B independently represents a C1-4alkylene or alkenylene chain, and W′ represents an electron withdrawing group or a group obtained by reduction of an electron withdrawing group; and in which said polyethylene glycol portion is or includes a pendant polyethylene glycol chain which has a terminal end group of formula —CH2CH2OR in which R represents a hydrogen atom, an alkyl group, or an optionally substituted aryl group. Also claimed are a method for making such a conjugate, and novel reagents useful in that method.